Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
  • Solutions
  • Sectors
  • Careers
Apr 2017
Joint Global Coordinator & Joint Bookrunner
€ 25.1 million
Accelerated Bookbuild Offering


Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer

  • Placement of 1,596,527 new shares, representing 10% of Nanobiotix’ pre-deal outstanding share capital
  • Issue price of €15.75 per share represented a limited 1.4% discount versus the year-to-date average closing price
  • Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner in this transaction

Fully focused on your future

Private Banking

  • Offices
  • Entrepreneurs
  • Doctors
  • Executives
  • Business Professionals
  • Wealth Management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions

Investment Management

Investment Banking

© Van Lanschot Kempen NV 2023
About us
Security and fraud awareness
Privacy & cookies